Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of pretreatment with mecamylamine (ME), hexamethonium (C-6), d-tubocurarine (DTC), atropine (AT), muscarinic agents 5-methylfurmethide (5-MFT) and O-ethylcholine (EtCh), physostigmine (PH) and cholineacetyltransferase inhibitors 2-benzoyl ethyltrimethylammonium (BETA) and N-naphthylvinylpyridine (NVP) were studied on the lethal action of phencyclidine (
PCP
) in male Swiss mice. The LD50 of
PCP
(237 mumol/kg, i.p.) significantly increased by 19% and 10% in ME (14.9 mumol/kg) and PH (0.08 mumol/kg) pretreated groups, respectively. The combined ME and PH pretreatment potentiated the survival of the mice. C-6 (7.3 mumol/kg), DTC (0.11 mumol/kg), AT (14.4 mumol/kg), 5-
MFT
(1.4 mumol/kg), EtCh (1.7 mumol/kg), BETA (88 mumol/kg) or NVP (74.7 mumol/kg) pretreatment had no significant effect on the LD50 of
PCP
. However, peripheral parasympathetic effects (defecation, urination, salivation, and lacrimation) of 5-
MFT
and EtCH in mice were abolished by
PCP
. Furthermore, low doses of
PCP
potentiated the peripheral signs in animals pretreated with 5-
MFT
or EtCh which, however, were abolished by higher doses of
PCP
. In vivo, administration of
PCP
was found to have no effect on brain cholinesterase (ChE) activity. These observations have indicated the possibility of central cholinergic mediation during acute toxicity of
PCP
.
...
PMID:Influence of cholinergic modifiers on phencyclidine-induced acute toxicity. 685 59
